FIGURE 7 | (A) Different pathways between the high-risk and low-risk groups. (B) Enrichment analyses of biological functions and pathways in the high- and low- risk group. (C) Single-sample gene set enrichment analysis of immune status between low- and high-risk subgroups. (D – M) Correlation between the distribution of tumor immune cells and value of NRlncRNA riskScore. (N, O) Comparisons of the expression levels of immune checkpoints between two groups. (P) The immune cell bubble of risk groups. (Q – S) . Treatment effects of CTLA-4 or PD-1 and combined CTLA-4 and PD-1 were evaluated in patients with high and low riskScores. (Q) CTLA-4 treatment group, (R) PD-1 treatment group, and (S) CTLA-4 and PD-1 combined treatment group. *P<0.05; **P<0.01; ***P<0.001. ns,